pharmaceutical

InterMune Shares Soar After FDA Panel Backs Drug

InterMune shares soared over 60% after hours after it came closer to FDA approval of its experimental treatment for a fatal lung disease. An advisory panel voted to approve the drug despite questionable effectiveness, given that the disease has no cure and patients need reason to hope.

Top Court Ruling Could Spell Danger for American Industry

The Supreme Court in January gave corporations unlimited power to spend money on political campaigns, a move that could sway politicians in favor of big companies. As a result, Washington could become more inclined to rule in favor of the companies that it is supposed to regulate. The result could be ominous.

Genzyme's bad year gets worse: Experimental kidney drug a no-go

Amgen's troubles keep compounding; Aranesp studies reveal greater risks

Heartburn drug illuminates growing mistrust of pharmaceuticals

Sanofi-Aventis buys Merck's stake in Merial for $4 billion

Big dosage, big profit: Does Genzyme encourage larger dosages than we need?

Will Wal-Mart make drug retailers sick?

Merck merges with Schering-Plough in yet another Big Pharma mega-deal

Get help paying for your prescription medications